Skip to main content
Erschienen in: Journal of Neurology 5/2018

24.02.2018 | Original Communication

Mild cognitive impairment in Parkinson’s disease: the Parkinson’s disease cognitive study (PACOS)

verfasst von: Roberto Monastero, Calogero Edoardo Cicero, Roberta Baschi, Marco Davì, Antonina Luca, Vincenzo Restivo, Chiara Zangara, Brigida Fierro, Mario Zappia, Alessandra Nicoletti

Erschienen in: Journal of Neurology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Approximately 30% of Parkinson’s disease (PD) patients show impaired cognitive performance, which is suggestive of Mild Cognitive Impairment (MCI), representing a predictor of dementia, especially when present at diagnosis. The objective of the study was to evaluate the frequency and clinical predictors of MCI in a large hospital-based cohort of PD patients. We collected cross-sectional data from the Parkinson’s disease cognitive impairment study (PACOS), a multicenter study involving two Movement Disorder centers, which are located in south Italy. The PD subjects were diagnosed according to the UK Brain Bank criteria and they underwent an extensive neuropsychological assessment. PD–MCI was diagnosed according to the Movement Disorder Society task force criteria for MCI. PD severity was evaluated in accordance with the Unified PD Rating Scale-Motor Examination (UPDRS-ME) and the Hoehn and Yahr scales. The study included 659 PD patients (57.5% men; mean age 67.0 ± 9.7 years), with a mean disease duration of 3.8 ± 4.6 years and a mean UPRDS-ME score of 25.8 ± 12.3. PD–MCI was diagnosed in 261 (39.6%) subjects and in 82 (31.7%) of 259 newly diagnosed patients (disease duration ≤ 1 year). An amnestic MCI multidomain phenotype was the most frequent MCI subtype (39.1% of the overall sample and 43.9% in newly diagnosed PD). A positive significant association between MCI, age and motor scores was found at multivariate logistic regression analysis, while a negative association was observed between educational level and MCI. In conclusion and in agreement with the literature data, the prevalence of MCI recorded in the PACOS sample was approximately 40 and 32% amongst newly diagnosed patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Williams-Gray CH, Mason SL, Evans JR et al (2013) The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 84:1258–1264CrossRefPubMed Williams-Gray CH, Mason SL, Evans JR et al (2013) The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 84:1258–1264CrossRefPubMed
2.
Zurück zum Zitat Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183–194CrossRefPubMed Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183–194CrossRefPubMed
3.
Zurück zum Zitat Litvan I, Goldman JG, Tröster AI et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement Disorder Society Task Force guidelines. Mov Disord 27:349–356CrossRefPubMedPubMedCentral Litvan I, Goldman JG, Tröster AI et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement Disorder Society Task Force guidelines. Mov Disord 27:349–356CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Pedersen KF, Larsen JP, Tysnes OB, Alves G (2013) Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian Park West Study. JAMA Neurol 70:580–586CrossRefPubMed Pedersen KF, Larsen JP, Tysnes OB, Alves G (2013) Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian Park West Study. JAMA Neurol 70:580–586CrossRefPubMed
6.
Zurück zum Zitat Cholerton BA, Zabetian CP, Wan JY et al (2014) Evaluation of mild cognitive impairment subtypes in Parkinson’s disease: MCI subtypes in Parkinson’s disease. Mov Disord 29:756–764CrossRefPubMedPubMedCentral Cholerton BA, Zabetian CP, Wan JY et al (2014) Evaluation of mild cognitive impairment subtypes in Parkinson’s disease: MCI subtypes in Parkinson’s disease. Mov Disord 29:756–764CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Pedersen KF, Larsen JP, Tysnes OB, Alves G (2017) Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. Neurology 88:767–774CrossRefPubMed Pedersen KF, Larsen JP, Tysnes OB, Alves G (2017) Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. Neurology 88:767–774CrossRefPubMed
9.
Zurück zum Zitat Domellöf ME, Ekman U, Forsgren L, Elgh E (2015) Cognitive function in the early phase of Parkinson’s disease, a five-year follow-up. Acta Neurol Scand 132:79–88CrossRefPubMed Domellöf ME, Ekman U, Forsgren L, Elgh E (2015) Cognitive function in the early phase of Parkinson’s disease, a five-year follow-up. Acta Neurol Scand 132:79–88CrossRefPubMed
10.
Zurück zum Zitat Hoogland J, Boel JA, de Bie RMA et al MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease” (2017) Mild cognitive impairment as a risk factor for Parkinson’s disease dementia: MCI as a risk factor for Parkinson’s disease dementia. Mov Disord 32:1056–1065 Hoogland J, Boel JA, de Bie RMA et al MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease” (2017) Mild cognitive impairment as a risk factor for Parkinson’s disease dementia: MCI as a risk factor for Parkinson’s disease dementia. Mov Disord 32:1056–1065
11.
Zurück zum Zitat Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752CrossRefPubMedPubMedCentral Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22:1689–1707CrossRefPubMed Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22:1689–1707CrossRefPubMed
13.
Zurück zum Zitat Fahn S, Elton RL, the members of the UPDRS development committee (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB (eds) Recent developments in Parkinson’s disease. MacMillan, London, pp 153–163 Fahn S, Elton RL, the members of the UPDRS development committee (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB (eds) Recent developments in Parkinson’s disease. MacMillan, London, pp 153–163
14.
Zurück zum Zitat Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427–442CrossRefPubMed Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427–442CrossRefPubMed
15.
Zurück zum Zitat Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC (2013) How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale. Mov Disord 28:668–670CrossRefPubMed Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC (2013) How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale. Mov Disord 28:668–670CrossRefPubMed
16.
Zurück zum Zitat Folstein MF, Folstein SE, McHugh PR (1975) ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMed Folstein MF, Folstein SE, McHugh PR (1975) ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMed
17.
Zurück zum Zitat Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW (1963) Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 185:914–919CrossRefPubMed Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW (1963) Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 185:914–919CrossRefPubMed
18.
Zurück zum Zitat Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572CrossRefPubMed Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572CrossRefPubMed
20.
Zurück zum Zitat Schrag A, Barone P, Brown RG et al (2007) Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 22:1077–1092CrossRefPubMedPubMedCentral Schrag A, Barone P, Brown RG et al (2007) Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 22:1077–1092CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Novelli G, Papagno C, Capitani E et al (1986) Tre test clinici di memoria verbale a lungo termine: Taratura su soggetti normali. Arch Psicol Neurol Psichiatria 47:278–296 Novelli G, Papagno C, Capitani E et al (1986) Tre test clinici di memoria verbale a lungo termine: Taratura su soggetti normali. Arch Psicol Neurol Psichiatria 47:278–296
22.
Zurück zum Zitat Novelli G, Papagno C, Capitani E et al (1986) Tre test clinici di ricerca e produzione lessicale. Taratura su soggetti normali. Archivio di Psicologia, Neurologia e Psichiatria 47:477–506 Novelli G, Papagno C, Capitani E et al (1986) Tre test clinici di ricerca e produzione lessicale. Taratura su soggetti normali. Archivio di Psicologia, Neurologia e Psichiatria 47:477–506
23.
Zurück zum Zitat Spinnler H, Tognoni G (1987) Italian Group on the Neuropsychological Study of Ageing: Italian standardization and classification of neuropsychological tests. Ital J NeurolSci 6(suppl 8):1–120 Spinnler H, Tognoni G (1987) Italian Group on the Neuropsychological Study of Ageing: Italian standardization and classification of neuropsychological tests. Ital J NeurolSci 6(suppl 8):1–120
24.
Zurück zum Zitat Luzzatti C, Willmes K, De Bleser R et al (1994) New normative data for the Italian version of the Aachen Aphasia Test (AAT). Arch Psicol Neurol Psichiatria 55:1086–1131 Luzzatti C, Willmes K, De Bleser R et al (1994) New normative data for the Italian version of the Aachen Aphasia Test (AAT). Arch Psicol Neurol Psichiatria 55:1086–1131
25.
Zurück zum Zitat Carlesimo GA, Caltagirone C, Gainotti G (1996) The Mental Deterioration Battery: normative data, diagnostic reliability and quantitative analyses of cognitive impairment. Eur Neurol 36:378–384CrossRefPubMed Carlesimo GA, Caltagirone C, Gainotti G (1996) The Mental Deterioration Battery: normative data, diagnostic reliability and quantitative analyses of cognitive impairment. Eur Neurol 36:378–384CrossRefPubMed
26.
Zurück zum Zitat Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M, Laiacona M, Capitani E (1996) Trail making test: normative values from 287 normal adult controls. Ital J Neurol Sci 17:305–309CrossRefPubMed Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M, Laiacona M, Capitani E (1996) Trail making test: normative values from 287 normal adult controls. Ital J Neurol Sci 17:305–309CrossRefPubMed
27.
Zurück zum Zitat Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A (2002) Una versione abbreviata del test di Stroop: dati normativi nella popolazione Italiana. Nuova Riv Neurol 12:111–115 Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A (2002) Una versione abbreviata del test di Stroop: dati normativi nella popolazione Italiana. Nuova Riv Neurol 12:111–115
28.
Zurück zum Zitat Appollonio I, Leone M, Isella V et al (2005) The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci 26:108–116CrossRefPubMed Appollonio I, Leone M, Isella V et al (2005) The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci 26:108–116CrossRefPubMed
29.
Zurück zum Zitat Caffarra P, Gardini S, Zonato F et al (2011) Italian norms for the Freedman version of the Clock Drawing Test. J Clin Exp Neuropsychol 33:982–988CrossRefPubMed Caffarra P, Gardini S, Zonato F et al (2011) Italian norms for the Freedman version of the Clock Drawing Test. J Clin Exp Neuropsychol 33:982–988CrossRefPubMed
30.
Zurück zum Zitat Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653CrossRefPubMed Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653CrossRefPubMed
31.
Zurück zum Zitat Litvan I, Aarsland D, Adler CH et al (2011) MDS task force on mild cognitive impairment in Parkinson’s disease: critical review of PD–MCI. Mov Disord 26:1814–1824CrossRefPubMedPubMedCentral Litvan I, Aarsland D, Adler CH et al (2011) MDS task force on mild cognitive impairment in Parkinson’s disease: critical review of PD–MCI. Mov Disord 26:1814–1824CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G, Norwegian ParkWest Study Group (2009) Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest Study. Neurology 72:1121–1126CrossRefPubMed Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G, Norwegian ParkWest Study Group (2009) Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest Study. Neurology 72:1121–1126CrossRefPubMed
33.
Zurück zum Zitat Monastero R, Di Fiore P, Ventimiglia GD et al (2012) Prevalence and profile of mild cognitive impairment in Parkinson’s disease. Neurodegener Dis 10:187–190CrossRefPubMed Monastero R, Di Fiore P, Ventimiglia GD et al (2012) Prevalence and profile of mild cognitive impairment in Parkinson’s disease. Neurodegener Dis 10:187–190CrossRefPubMed
34.
Zurück zum Zitat Goldman JG, Holden S, Bernard B, Ouyang B, Goetz CG, Stebbins GT (2013) Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson’s disease. Mov Disord 28:1972–1979CrossRefPubMedPubMedCentral Goldman JG, Holden S, Bernard B, Ouyang B, Goetz CG, Stebbins GT (2013) Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson’s disease. Mov Disord 28:1972–1979CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Marras C, Armstrong MJ, Meaney CA et al (2013) Measuring mild cognitive impairment in patients with Parkinson’s disease. Mov Disord 28:626–633CrossRefPubMedPubMedCentral Marras C, Armstrong MJ, Meaney CA et al (2013) Measuring mild cognitive impairment in patients with Parkinson’s disease. Mov Disord 28:626–633CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Cholerton BA, Zabetian CP, Quinn JF et al (2013) Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Park Dis 3:205–214 Cholerton BA, Zabetian CP, Quinn JF et al (2013) Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Park Dis 3:205–214
37.
Zurück zum Zitat Yarnall AJ, Breen DP, Duncan GW et al (2014) Characterizing mild cognitive impairment in incident Parkinson disease The ICICLE-PD Study. Neurology 82:308–316CrossRefPubMedPubMedCentral Yarnall AJ, Breen DP, Duncan GW et al (2014) Characterizing mild cognitive impairment in incident Parkinson disease The ICICLE-PD Study. Neurology 82:308–316CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Cereda E, Cilia R, Klersy C et al (2016) Dementia in Parkinson’s disease: is male gender a risk factor? Parkinsonism Relat Disord 26:67–72CrossRefPubMed Cereda E, Cilia R, Klersy C et al (2016) Dementia in Parkinson’s disease: is male gender a risk factor? Parkinsonism Relat Disord 26:67–72CrossRefPubMed
39.
Zurück zum Zitat Hu MTM, Szewczyk-Królikowski K, Tomlinson P et al (2014) Predictors of cognitive impairment in an early stage Parkinson’s disease cohort. Mov Disord 29:351–359CrossRefPubMedPubMedCentral Hu MTM, Szewczyk-Królikowski K, Tomlinson P et al (2014) Predictors of cognitive impairment in an early stage Parkinson’s disease cohort. Mov Disord 29:351–359CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM (2017) Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study. Lancet Neurol 16:66–75CrossRefPubMed Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM (2017) Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study. Lancet Neurol 16:66–75CrossRefPubMed
41.
Zurück zum Zitat Zhu K, van Hilten JJ, Marinus J (2014) Predictors of dementia in Parkinson’s disease; findings from a 5-year prospective study using the SCOPA-COG. Parkinsonism Relat Disord 20:980–985CrossRefPubMed Zhu K, van Hilten JJ, Marinus J (2014) Predictors of dementia in Parkinson’s disease; findings from a 5-year prospective study using the SCOPA-COG. Parkinsonism Relat Disord 20:980–985CrossRefPubMed
42.
Zurück zum Zitat Broeders M, De Bie RMA, Velseboer DC, Speelman JD, Muslimovic D, Schmand B (2013) Evolution of mild cognitive impairment in Parkinson disease. Neurology 81:346–352CrossRefPubMed Broeders M, De Bie RMA, Velseboer DC, Speelman JD, Muslimovic D, Schmand B (2013) Evolution of mild cognitive impairment in Parkinson disease. Neurology 81:346–352CrossRefPubMed
43.
Zurück zum Zitat Kalbe E, Rehberg SP, Heber I, Kronenbuerger M et al (2016) Subtypes of mild cognitive impairment in patients with Parkinson’s disease: evidence from the LANDSCAPE study. J Neurol Neurosurg Psychiatry 87:1099–1105CrossRefPubMed Kalbe E, Rehberg SP, Heber I, Kronenbuerger M et al (2016) Subtypes of mild cognitive impairment in patients with Parkinson’s disease: evidence from the LANDSCAPE study. J Neurol Neurosurg Psychiatry 87:1099–1105CrossRefPubMed
44.
Zurück zum Zitat Santangelo G, Vitale C, Picillo M et al (2015) Mild Cognitive Impairment in newly diagnosed Parkinson’s disease: a longitudinal prospective study. Parkinsonism Relat Disord 21:1219–1226CrossRefPubMed Santangelo G, Vitale C, Picillo M et al (2015) Mild Cognitive Impairment in newly diagnosed Parkinson’s disease: a longitudinal prospective study. Parkinsonism Relat Disord 21:1219–1226CrossRefPubMed
45.
47.
Zurück zum Zitat Kehagia AA, Barker RA, Robbins TW (2013) Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis 11:79–92CrossRefPubMed Kehagia AA, Barker RA, Robbins TW (2013) Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis 11:79–92CrossRefPubMed
Metadaten
Titel
Mild cognitive impairment in Parkinson’s disease: the Parkinson’s disease cognitive study (PACOS)
verfasst von
Roberto Monastero
Calogero Edoardo Cicero
Roberta Baschi
Marco Davì
Antonina Luca
Vincenzo Restivo
Chiara Zangara
Brigida Fierro
Mario Zappia
Alessandra Nicoletti
Publikationsdatum
24.02.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 5/2018
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-018-8800-4

Weitere Artikel der Ausgabe 5/2018

Journal of Neurology 5/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.